a levodopa - search results

European Union - English - EMA (European Medicines Agency)

levodopa/carbidopa/entacapone orion

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

United States - English - NLM (National Library of Medicine)

carbidopa, levodopa and entacapone tablet, film coated

wockhardt usa llc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 50 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson's disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. - to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to in

United States - English - NLM (National Library of Medicine)

duopa- carbidopa and levodopa suspension

abbvie inc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 20 mg in 1 ml - duopa® is indicated for the treatment of motor fluctuations in patients with advanced parkinson’s disease. duopa is contraindicated in patients who are currently taking a nonselective monoamine oxidase (mao) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective mao inhibitor. hypertension can occur if these drugs are used concurrently [see drug interactions ( 7.1 and 7.2 )] . risk summary there are no adequate data on the developmental risk associated with the use of duopa in pregnant women. in animal studies, carbidopa-levodopa has been shown to be developmentally toxic (including teratogenic effects) at clinically relevant doses (see data) . the estimated background risk of major birth defects and miscarriage in the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data when administ